2nd Quarter 2024 Financial Results Call C. Randal Mills PhD Chief Executive Officer Matt Ferguson Chief Financial Officer August 7, 2024 Forward-Looking Statements This presentation of Elutia Inc. ("Elutia," "we," "us," "our" or the "Company") (together with any other statements or information that we may make or discuss in connection herewith) contains forward-looking statements. All statements other than statements of historical facts, including but not limited to statements regarding the market potential ...

业绩总结 - H1 2024有机收入增长强劲，体积增长3.1%[6] - 可比EBIT增长7.5%，达到5.641亿欧元[13] - 预计2024年有机收入增长为8至12%，有机EBIT增长为7至12%[97] - 自由现金流为220.2百万欧元，股东回报增加19.2%[92] 用户数据 - Sparkling领域在H1 2024表现强劲，增长0.9%[17] - 能源领域增长迅猛，H1 2024增长32.8%[25] - 咖啡领域在H1 2024持续进展，增长21.6%[32] - 静态饮料和高端烈酒表现良好，H1 2024分别增长5.2%和17.3%[37] 未来展望 - 公司提到2024年展望和未来业绩[120] - 公司强调前瞻性陈述中存在风险和不确定性[121] 新产品和新技术研发 - 持续投资可持续性作为增长推动因素，推出回收押金计划在爱尔兰和匈牙利[44] 市场扩张和并购 - 预计2024年净财务成本为60至75百万欧元，可比税率为25%-27%[88]

Investor Presentation Second Quarter August 2024 DISCLAIMERS Forward-Looking Statements This presentation includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1996. The Company's actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "foreca ...

FY2024 Results Analyst and Media Briefing Loh Boon Chye, Chief Executive Officer Ng Yao Loong, Chief Financial Officer 8 August 2024 Singapore Exchange Commodities | Equity Derivatives | Fixed Income | FX | Indices | Securities Forward Looking Statements This presentation may contain forward-looking statements that involve assumptions, risks and uncertainties. Statements in this presentation that are not historical facts are statements of future expectations with respect to the financial conditions, results ...

Forward Air 2Q24 Earnings Presentation August 7, 2024 O ropor o o Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. ...

Investor Presentation Second Quarter 2024 Legal Disclaimer FORWARD-LOOKING STATEMENTS. Certain statements in this presentation may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, references to: potential or expected future cash flows; estimated or expected returns, sometimes referred to as initial IRR, updated IRR, expected IRR, or current-to-maturity IRR; potential discount rates; potential future investments; e ...

Second Quarter 2024 Operating & Financial Results Conference Call / Webinar With additional focus on preliminary patient data and clinical readouts for Phase 2 LP-300 Harmonic Trial August 8th, 2024 4:30 PM Eastern Time NASDAQ :LTRN Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other ...

f n A 1 1 02724 EARNINGS PRESENTALION L AUGUST 7, 2024 es also served in the context with the large and the large an y v Mining Royalty Lands Safe Harbor Disclosures Investors are cautioned that any statements in this press release which relate to the future are, by their nature, subject to risks and uncertainties that could cause actual results and events to differ materially from those indicated in such forwardlooking statements. These include, but are not limited to: the possibility that we may be unable ...

业绩总结 - FYARRO®自上市以来销售额达到了51.1百万美元，反映了持续稳定的需求增长[9] - FYARRO®在2024年第二季度的净销售额为6.2百万美元，较2024年第一季度增长14%[13] - FYARRO®在美国主要肿瘤中心的产品需求依然强劲，年至今账户再订购率约为80%[15] 产品研发 - PRECISION1注册意向性试验正在进行中，预计将于年底完成[10] - 公司的研发费用主要用于PRECISION1、EEC和NETs试验[17] - PRECISION1的2/3中期分析预计在第三季度公布，同时也预计在2025年初公布120名患者的完整结果[19] 财务状况 - 公司截至2024年6月30日的现金、现金等价物和短期投资总额为78.6百万美元，预计资金可以支持运营至2025年第四季度[11] 未来展望 - 公司预计在2025年初向FDA提交nab-sirolimus用于肿瘤不可知指标的申请[21]

财务结果 - 公司Q2 2024财务结果显示，营收为1.282亿美元，较去年同期下降3.4%[12] - 美国作物销售额为5,229万美元，较去年同期下降7%；非作物销售额为1,901万美元，较去年同期增长13%[14] - 国际销售额为5,690万美元，较去年同期下降5%[15] - 公司Q2 2024总净销售额为1.28亿美元，较去年同期下降3%[52] - 公司Q2 2024总成本销售额为9,044.6万美元，较去年同期增长1%[53] - 公司1H 2024总净销售额为2.6335亿美元，较去年同期增长2%[54] - 公司1H 2024总成本销售额为1.83171亿美元，较去年同期增长4%[55] 运营费用 - 公司Q2 2024运营费用占销售额的比例为36.6%，较去年同期增长7.1%[56] - 公司1H 2024运营费用占销售额的比例为31.6%，较去年同期增长2.7%[59]